<DOC>
	<DOCNO>NCT02455297</DOCNO>
	<brief_summary>The primary objective study assess objective response rate ( ORR ) patient relapse refractory MCL fail ibrutinib treatment unable tolerate ibrutinib .</brief_summary>
	<brief_title>Phase IIa Study Copanlisib Relapsed Refractory Mantle Cell Lymphoma ( MCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Histologically confirm MCL Patients previously receive treatment ibrutinib ( modify amendment 1 ) , include : Completion least 1 cycle treatment ibrutinib confirm evidence disease progression refractoriness treatment Discontinuation ibrutinib treatment early time due toxicity Measurable disease accord Lugano Classification At least 28 day 5 halflives , whichever short , completion anticancer treatment ( include , limited , immunotherapy , chemotherapy , target therapy biologic therapy ) start study treatment , exclude ibrutinib window may less minimum 3 day ( modify amendment 1 ) Availability fresh tumor tissue screen Male female patient ≥ 18 year old ECOG ( Eastern Cooperative Oncology Group ) performance status ≤ 2 Left ventricular ejection fraction ( LVEF ) echocardiogram multiple gated acquisition ( MUGA ) scan ≥ low limit normal ( LLN ) Institution Adequate bone marrow , liver renal function Any follow site ( ) disease : palpable lymph node visible image study , skin lesion , bone marrow involvement Current central nervous system ( CNS ) involvement lymphoma New York Heart Association ( NYHA ) class III IV heart disease Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month start study treatment Uncontrolled arterial hypertension despite optimal medical management ( per investigator 's assessment ) ( modify amendment 1 ) Type I II diabetes mellitus HbA1c &gt; 8.5 % screening ( modify amendment 1 ) Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 3 month start study treatment . However , patient recover ECOG performance status ≤ 2 he/she may enrol provide eligibility criterion meet Ongoing active infection Common Terminology Criteria Adverse Events ( CTCAE ) Grade ≥ 3 Known history human immunodeficiency virus ( HIV ) infection Acute chronic hepatitis B ( HBV ) hepatitis C ( HCV ) infection require concomitant treatment prohibit protocol ( i.e.immunosuppressive therapy ) History concurrent condition interstitial lung disease severity and/or severely impaired lung function ( judged investigator ) Prior treatment PI3K inhibitor ( ) Cytomegalovirus ( CMV ) PCR positive baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>